These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8375016)

  • 21. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation.
    Smith PJ; Desnoyers R; Blunt N; Giles Y; Patterson LH; Watson JV
    Cytometry; 1997 Jan; 27(1):43-53. PubMed ID: 9000584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
    McErlane V; Yakkundi A; McCarthy HO; Hughes CM; Patterson LH; Hirst DG; Robson T; McKeown SR
    J Gene Med; 2005 Jul; 7(7):851-9. PubMed ID: 15712360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A preclinical pharmacokinetic study of the bioreductive drug AQ4N.
    Loadman PM; Swaine DJ; Bibby MC; Welham KJ; Patterson LH
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):422-6. PubMed ID: 11259326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
    Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
    Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
    Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
    Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
    Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.
    Steward WP; Middleton M; Benghiat A; Loadman PM; Hayward C; Waller S; Ford S; Halbert G; Patterson LH; Talbot D
    Ann Oncol; 2007 Jun; 18(6):1098-103. PubMed ID: 17442658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
    Lee HH; Wilson WR; Denny WA
    Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
    Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.
    Nishida CR; Ortiz de Montellano PR
    J Med Chem; 2008 Aug; 51(16):5118-20. PubMed ID: 18681417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour cytochrome P450 and drug activation.
    Patterson LH; Murray GI
    Curr Pharm Des; 2002; 8(15):1335-47. PubMed ID: 12052211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
    Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
    Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND; Plumb JA; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
    McKeown SR; Friery OP; McIntyre IA; Hejmadi MV; Patterson LH; Hirst DG
    Br J Cancer Suppl; 1996 Jul; 27():S39-42. PubMed ID: 8763843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
    Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
    Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
    Naylor MA; Stephens MA; Nolan J; Sutton B; Tocher JH; Fielden EM; Adams GE; Stratford IJ
    Anticancer Drug Des; 1993 Dec; 8(6):439-61. PubMed ID: 8286012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
    Bailey SM; Suggett N; Walton MI; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.
    Siim BG; Hicks KO; Pullen SM; van Zijl PL; Denny WA; Wilson WR
    Biochem Pharmacol; 2000 Oct; 60(7):969-78. PubMed ID: 10974206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical radiosensitizers for use in radiotherapy.
    Wardman P
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.